By 2026, the German biotechnology company BioNTech intends to launch the first cancer vaccines on the market. The founders of the company, Ugur Sahin and Ozlem Türeci, announced this in an interview with Focus magazine, writes snob.ru.

BioNTech specialists managed to obtain antibodies against one type of lung cancer. Work is underway on a vaccine against breast cancer. By the end of 2024, Sahin, Türeci and their team plan to complete trials and begin registration of these vaccines.

The company is currently conducting clinical trials on 30 types of cancer, including cancer of the skin, colon, uterus, prostate and other organs. By 2030, BioNTech intends to create a portfolio of innovative methods to combat tumors.

According to Türeci, chemotherapy, although a powerful tool for treating tumors, can cause serious harm to the body. BioNTech vaccines activate the patient’s own defense system without causing harm to him.

BioNTech already has a successful track record of developing immunotherapeutics. The company was founded in 2008 and over the course of 11 years received support from the Bill and Melinda Gates Foundation to develop vaccines against HIV, tuberculosis and other diseases. In 2020, BioNTech, together with Pfizer, became one of the first manufacturers of a vaccine against COVID-19.